Scinai Immunotherapeutics (SCNI) Current Deferred Revenue (2024 - 2025)
Scinai Immunotherapeutics' (SCNI) quarterly Current Deferred Revenue came in at $90000.0 in Q4 2025, down 60.0% year-on-year from $225000.0 in Q4 2024, and down 60.0% quarter-over-quarter from $225000.0 in Q4 2024.
Scinai Immunotherapeutics (SCNI) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Scinai Immunotherapeutics has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $90000.0 for Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $90000.0, down 60.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $90000.0 (down 60.0% YoY), and the FY2025 annual result was $90000.0, down 60.0% from the prior year.
- Current Deferred Revenue came in at $90000.0 for Q4 2025 at Scinai Immunotherapeutics, down from $225000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $225000.0 in Q4 2024 to a low of $90000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Scinai Immunotherapeutics | 3.02 Bn | 988.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90,000.00 |
| Dec 31, 2024 | 225,000.00 |